These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25724458)

  • 1. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression.
    Froeling FE; Kocher HM
    Gastroenterology; 2015 Apr; 148(4):849-50. PubMed ID: 25724458
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.
    Sherman MH; Yu RT; Engle DD; Ding N; Atkins AR; Tiriac H; Collisson EA; Connor F; Van Dyke T; Kozlov S; Martin P; Tseng TW; Dawson DW; Donahue TR; Masamune A; Shimosegawa T; Apte MV; Wilson JS; Ng B; Lau SL; Gunton JE; Wahl GM; Hunter T; Drebin JA; O'Dwyer PJ; Liddle C; Tuveson DA; Downes M; Evans RM
    Cell; 2014 Sep; 159(1):80-93. PubMed ID: 25259922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro.
    Colston KW; James SY; Ofori-Kuragu EA; Binderup L; Grant AG
    Br J Cancer; 1997; 76(8):1017-20. PubMed ID: 9376260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy.
    Anbil S; Pigula M; Huang HC; Mallidi S; Broekgaarden M; Baglo Y; De Silva P; Simeone DM; Mino-Kenudson M; Maytin EV; Rizvi I; Hasan T
    Mol Cancer Ther; 2020 Jun; 19(6):1308-1319. PubMed ID: 32220968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel drug targets based on association between inflammation and pancreatic ductal adenocarcinoma.
    Saif MW
    JOP; 2010 Jul; 11(4):403-4; author reply 411. PubMed ID: 20601821
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of vitamin D receptor as a potential prognostic factor and therapeutic target in pancreatic cancer.
    Wang K; Dong M; Sheng W; Liu Q; Yu D; Dong Q; Li Q; Wang J
    Histopathology; 2015 Sep; 67(3):386-97. PubMed ID: 25641222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Optimal duration and timing of adjuvant chemotherapy after resection for pancreatic ductal adenocarcinoma].
    Strobel O; Büchler MW
    Chirurg; 2014 Jun; 85(6):543. PubMed ID: 24824005
    [No Abstract]   [Full Text] [Related]  

  • 10. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic cancer: New insights into PDAC growth promotion via a BAG3-mediated paracrine loop.
    Ray K
    Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):669. PubMed ID: 26577348
    [No Abstract]   [Full Text] [Related]  

  • 12. Timing versus duration of adjuvant therapy for pancreatic cancer: all the lessons we need in life are taught to us as children.
    Chan E; Berlin J
    J Clin Oncol; 2014 Feb; 32(6):487-8. PubMed ID: 24419124
    [No Abstract]   [Full Text] [Related]  

  • 13. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
    Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
    Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
    [No Abstract]   [Full Text] [Related]  

  • 15. Vitamin D and pancreatic cancer.
    Barreto SG; Neale RE
    Cancer Lett; 2015 Nov; 368(1):1-6. PubMed ID: 26276715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The case for a stratified application of targeted agents against pancreatic cancer.
    Bijlsma MF
    EBioMedicine; 2021 May; 67():103344. PubMed ID: 33910122
    [No Abstract]   [Full Text] [Related]  

  • 17. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
    Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
    Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible electroporation: a novel pancreatic cancer therapy.
    Weiss MJ; Wolfgang CL
    Curr Probl Cancer; 2013; 37(5):262-5. PubMed ID: 24331180
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines.
    Kawa S; Yoshizawa K; Nikaido T; Kiyosawa K
    J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):173-7. PubMed ID: 16039115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma.
    Gautam SK; Kumar S; Cannon A; Hall B; Bhatia R; Nasser MW; Mahapatra S; Batra SK; Jain M
    Expert Opin Ther Targets; 2017 Jul; 21(7):657-669. PubMed ID: 28460571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.